Biotie Therapies Oy is a member company of Pharma Industry Finland (PIF) and follows the PIF Code of Ethics, which implements the Disclosure Code set forth by the European Federation of Pharmaceutical Industries and Associations (EFPIA). The EFPIA Disclosure Code (2014) requires all EFPIA member companies to document and disclose certain Transfers of Value made directly, or indirectly, to or for the benefit of Healthcare Professionals (HCPs) or Healthcare Organizations (HCOs). Biotie discloses all Transfers of Value to HCPs and HCOs in accordance with its commitment to the PIF Code of Ethics and EFPIA Disclosure Code (2014) and supports principles of responsible transparency to enhance relationships between industry, HCPs and patients.
|2017 EFPIA Disclosure|
|2016 EFPIA Disclosure|
|2015 EFPIA Disclosure|
You are now leaving the Acorda.com site. By clicking "Ok", you will be leaving this website (sponsored by Acorda Therapeutics, Inc.) to enter an external and entirely independent website.
Acorda.com provides this link as a service and assumes no responsibility for any information presented on external websites.
If you’ve been impacted by Hurricane Harvey, Irma, or Maria, and have concerns about your Ampyra (dalfampridine) prescription, please contact your Specialty Pharmacy or Ampyra Patient Support Services at (888) 881-1918
Acorda has acquired Biotie Therapies. We invite you to explore www.acorda.com to learn more about our company, including our continued development of BIotie clinical programs for tozadenant, SYN120 and BTT1023. Information regarding transfers of value made to healthcare professionals and healthcare organizations in connection with Biotie’s clinical development programs is also available.